A growing number of clinicians rely on AdaptDx to detect age-related macular degeneration in their adult patients. Our customers tell the story of how they’re fighting against blindness caused by AMD.
The primary goal of every optometrist is to maximize and preserve the vision of their patients. The AdaptDx is the best device available for the earliest detection of reduced dark adaptation of the retina, usually secondary to AMD. Early detection gives my patients the best chance for long term retention of their vision, thereby achieving their vision goals and my practice goals.
I started using my AdaptDx this past July (2017), and it has already completely changed my approach to AMD for the better. In terms of both detecting undiagnosed AMD and confirming patients with early AMD, I can say with confidence that it's preserving future vision for my patients.
The AdaptDx has been a great addition to my office. This device allows me to find patients with AMD much sooner than we've ever been able to do. We know that 1 out of 3 Americans over the age of 75 has some form of AMD. But why wait until it's obvious to start therapy?
We have a large retirement population here in Myrtle Beach, so we see a lot of AMD. We invested in the AdaptDx because we know it’s going to help us take better care of our AMD patients, as well as identify so many others who are at risk for developing this devastating disease.
There is no better way to grow a corporate practice than having the newest and most advanced technology like the AdaptDx. This makes my practice stand out from other practices.
The AdaptDx is a complete paradigm shift in the management and vision loss prevention of AMD. We no longer have the "watch & wait" approach with AMD. Our new proactive approach to this sight threatening disease is utilizing the AdaptDx to diagnose AMD due to physiological changes that occur YEARS before any drusen and structural changes are visible. Then, we start patients on a treatment plan and follow up care significantly earlier, resulting in greatly improved outcomes for our patients!!
The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.
If you had a crystal ball to predict glaucoma, diabetic retinopathy or AMD would you not take advantage of it? We have early diagnostic strategies for all three. Ganglion cell loss and capillary density reduction are sentinels for glaucoma and DR, respectively. Impaired dark adaptation is the gold standard bio marker for sub clinical AMD. The AdaptDx is the FDA-cleared instrument for this important measurement.
It would be unimaginable nowadays to diagnose glaucoma without both structural and functional testing. With today’s technology, the same can be said for AMD as functional testing complements structural findings for the earliest indications of the disease
Now that we are using the AdaptDx to diagnose AMD earlier and actively manage disease progression, I’m confident we will improve outcomes in both eyes by catching CNV before significant vision loss occurs.